Uncategorized
VIDEO: Holland discusses safety, efficacy of KPI-121 ophthalmic suspension 0.25%
In this video perspective from the virtual AAO annual meeting, Edward J. Holland, MD, discusses clinical trial data for Eysuvis (KPI-121 0.25%; loteprednol etabonate ophthalmic suspension, Kala), which was recently approved by the FDA.